[Treatment using Motilium of gastro-esophageal reflux associated with respiratory manifestations in children].
Eighteen children aged 1 month to 12 years 8 months (mean age, 4.9 years) with pH-metry proven gastroesophageal reflux (GOR)-associated chronic respiratory disorders were treated with Motilium, 2 mg/kg/d in four divided doses, for three months. The incidence of each of the respiratory manifestations decreased, and their cumulative score improved significantly at the end of the treatment period. Patient daily self-assessment scores also fell, but not significantly. Twenty-one hour pH recordings showed a significant reduction in the duration of nocturnal episodes below 4 (2.8 +/- 0.9% versus 8.2 +/- 2.6%, p less than 0.05). No side effects were recorded. Domperidone provides satisfactory control of nocturnal GOR and therefore emerges as a valuable agent for the treatment of chronic GOR-associated respiratory disorders in childhood.
Dupont
C
C
Molkhou
P
P
Petrovic
N
N
Fraitag
B
B
D001249:Asthma / Q000517:prevention & control*; D001991:Bronchitis / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D003371:Cough / Q000517:prevention & control*; D004294:Domperidone / Q000008:administration & dosage / Q000627:therapeutic use*; D005764:Gastroesophageal Reflux / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007223:Infant; D007827:Laryngitis / Q000517:prevention & control; D012008:Recurrence
D004294:Domperidone
Traitement par Motilium du reflux gastro-oesophagien associé à des manifestations respiratoires chez l'enfant.